Glycomimetics Inc GLYC
We take great care to ensure that the data presented and summarized in this overview for GLYCOMIMETICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GLYC
View all-
Bvf Inc San Francisco, CA9.54MShares$2.58 Million0.86% of portfolio
-
Artal Group S.A. Luxembourg, N48.59MShares$2.32 Million1.39% of portfolio
-
Nea Management Company, LLC Timonium, MD3.84MShares$1.04 Million0.81% of portfolio
-
Octagon Capital Advisors LP New York, NY3MShares$810,0001.41% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.76MShares$745,7340.0% of portfolio
-
Axa S.A. Paris, I01.59MShares$428,6900.01% of portfolio
-
Goldman Sachs Group Inc New York, NY1.11MShares$300,9710.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny747KShares$201,6770.0% of portfolio
-
Black Rock Inc. New York, NY733KShares$197,7930.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA555KShares$149,7400.0% of portfolio
Latest Institutional Activity in GLYC
Top Purchases
Top Sells
About GLYC
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Insider Transactions at GLYC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 29
2024
|
Mark Alan Goldberg |
BUY
Grant, award, or other acquisition
|
Direct |
4,584
+15.59%
|
$13,752
$3.0 P/Share
|
|
Mar 29
2024
|
Rachel K. King |
BUY
Grant, award, or other acquisition
|
Direct |
3,334
+0.64%
|
$10,002
$3.0 P/Share
|
|
Mar 29
2024
|
Daniel M Junius |
BUY
Grant, award, or other acquisition
|
Direct |
5,209
+5.02%
|
$15,627
$3.0 P/Share
|
|
Dec 29
2023
|
Mark Alan Goldberg |
BUY
Grant, award, or other acquisition
|
Direct |
5,827
+22.35%
|
$11,654
$2.36 P/Share
|
|
Dec 29
2023
|
Rachel K. King |
BUY
Grant, award, or other acquisition
|
Direct |
4,238
+0.82%
|
$8,476
$2.36 P/Share
|
|
Dec 29
2023
|
Patricia S Andrews |
BUY
Grant, award, or other acquisition
|
Direct |
5,191
+8.14%
|
$10,382
$2.36 P/Share
|
|
Sep 30
2023
|
Mark Alan Goldberg |
BUY
Grant, award, or other acquisition
|
Direct |
9,167
+38.87%
|
$9,167
$1.5 P/Share
|
|
Sep 30
2023
|
Rachel K. King |
BUY
Grant, award, or other acquisition
|
Direct |
6,667
+1.3%
|
$6,667
$1.5 P/Share
|
|
Sep 30
2023
|
Patricia S Andrews |
BUY
Grant, award, or other acquisition
|
Direct |
8,167
+13.26%
|
$8,167
$1.5 P/Share
|
|
Sep 22
2023
|
Edwin Rock Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
30,403
+7.49%
|
$30,403
$1.38 P/Share
|
|
Sep 21
2023
|
Edwin Rock Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
35,000
+9.21%
|
$35,000
$1.38 P/Share
|
|
Jun 01
2023
|
Scott Koenig |
BUY
Exercise of conversion of derivative security
|
Direct |
21,000
+36.36%
|
$0
$0.6 P/Share
|
|
May 17
2023
|
Brian M. Hahn SVP Finance, CFO |
SELL
Open market or private sale
|
Direct |
3,700
-6.51%
|
$3,700
$1.95 P/Share
|
|
May 10
2023
|
Daniel M Junius |
BUY
Open market or private purchase
|
Direct |
30,000
+24.34%
|
$30,000
$1.56 P/Share
|
|
May 08
2023
|
Bruce S Johnson SVP & Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
13,500
+8.85%
|
$13,500
$1.57 P/Share
|
|
Feb 24
2023
|
Invus Public Equities, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
100,000
+1.15%
|
$100,000
$1.7 P/Share
|
|
Feb 23
2023
|
Invus Public Equities, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
200,000
+2.3%
|
$200,000
$1.75 P/Share
|
|
Feb 22
2023
|
Invus Public Equities, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
150,000
+1.78%
|
$150,000
$1.79 P/Share
|
|
Feb 21
2023
|
Invus Public Equities, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
50,000
+0.61%
|
$50,000
$1.85 P/Share
|
|
Feb 17
2023
|
Invus Public Equities, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
200,000
+2.41%
|
$200,000
$1.7 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 52.4K shares |
|---|---|
| Open market or private purchase | 65.4K shares |